These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 18482049)

  • 1. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.
    Rogers CC; Alloway RR; Alexander JW; Cardi M; Trofe J; Vinks AA
    Clin Transplant; 2008; 22(3):281-91. PubMed ID: 18482049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics.
    Braun F; Schöcklmann H; Ziegler E; Kunzendorf U; Armstrong VW; Renders L
    Clin Pharmacol Ther; 2009 Oct; 86(4):411-5. PubMed ID: 19606088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM; Ekberg H; Mamelok RD; Oppenheimer F; Sánchez-Plumed J; Gentil MA; Hernandez D; Kuypers DR; Brunet M
    Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen.
    Greanya ED; Poulin E; Partovi N; Shapiro RJ; Al-Khatib M; Ensom MH
    Am J Health Syst Pharm; 2012 Jan; 69(2):134-42. PubMed ID: 22215359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC; van Gelder T; Sombogaard F; Shaw LM; van Hest RM; Mathot RA
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.
    Kuypers DR; Vanrenterghem Y; Squifflet JP; Mourad M; Abramowicz D; Oellerich M; Armstrong V; Shipkova M; Daems J
    Ther Drug Monit; 2003 Oct; 25(5):609-22. PubMed ID: 14508385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
    MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
    Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co-treated with tacrolimus: A population analysis.
    Yang CL; Sheng CC; Liao GY; Su Y; Feng LJ; Xia Q; Jiao Z; Xu DJ
    J Clin Pharm Ther; 2021 Dec; 46(6):1564-1575. PubMed ID: 34312870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil.
    Morissette P; Albert C; Busque S; St-Louis G; Vinet B
    Ther Drug Monit; 2001 Oct; 23(5):520-5. PubMed ID: 11591897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
    Nashan B; Saliba F; Durand F; Barcéna R; Herrero JI; Mentha G; Neuhaus P; Bowles M; Patch D; Bernardos A; Klempnauer J; Bouw R; Ives J; Mamelok R; McKay D; Truman M; Marotta P
    Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis.
    Stuckey L; Clark Ojo T; Park JM; Annesley T; Bartos C; Cibrik DM
    Ther Drug Monit; 2014 Apr; 36(2):148-51. PubMed ID: 24232127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
    McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies.
    Jiao Z; Zhong JY; Zhang M; Shi XJ; Yu YQ; Lu WY
    Eur J Clin Pharmacol; 2007 Jan; 63(1):27-37. PubMed ID: 17093994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.
    Tornatore KM; Meaney CJ; Wilding GE; Chang SS; Gundroo A; Cooper LM; Gray V; Shin K; Fetterly GJ; Prey J; Clark K; Venuto RC
    Clin Pharmacokinet; 2015 Apr; 54(4):423-34. PubMed ID: 25511793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.